Our study showed that the triple combination of the HDACi entinostat, a BETi, preferably OTX015, and cisplatin or a dual-acting HDAC/BET inhibitor plus cisplatin is highly synergistic in bladder carcinoma cell lines and completely reverses cisplatin resistance. Here, DNER is linked to urinary bladder carcinoma.